Logo

The US FDA Approves New Indication for Lilly's Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer with a BRAF V600E Mutation

Share this

The US FDA Approves New Indication for Lilly's Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer with a BRAF V600E Mutation

Shots:

  • The approval is based on P-III BEACON CRC trial evaluating Braftovi (300mg- qd) + Erbitux vs irinotecan + Erbitux or Folfiri + Erbitux in a ratio (1:1:1) in 441 patients with previously treated mCRC with a BRAF V600E mutation after prior therapy
  • Erbitux + Braftovi showed an improved OS; m-OS (8.4 vs 5.4mos.); ORR (20% vs 2%); CR (5% vs 2%); PR (15% vs 2%) and m-PFS (4.2 vs 1.5mos.)
  • Erbitux is the 1st anti-EGFR antibody approved in combination with encorafenib for adults with previously treated mCRC with a BRAF V600E mutation. On April 8- 2020- the FDA has approved Pfizer's encorafenib for the same indication

  | Ref: PR Newswire | Image: Forbes

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions